IP Library › Assignment 023973/0286
Patent Assignment
Reel/Frame 023973/0286

Release of Security Interest

Recorded: 2010-02-23 Pages: 67
Assignor
EOS HOLDINGS LLC, AS AGENT
Executed: 2010-02-17
Assignees
MDRNA, INC.
3830 MONTE VILLA PARKWAY, BOTHELL, WASHINGTON, 98021
MDRNA RESEARCH, INC.
3830 MONTE VILLA PARKWAY, BOTHELL, WASHINGTON, 98021
NASTECH PHARMACEUTICAL COMPANY, INC.
3830 MONTE VILLA PARKWAY, BOTHELL, WASHINGTON, 98021
Covered Properties (134)
Nanoparticles for Delivery of Nucleic Acids and Stable Double-Stranded Rna
Methods and Compositions for Enhancing Delivery of Double-Stranded Rna or a Double-Stranded Hybrid Nucleic Acid to Regulate Gene Expression in Mammalian Cells
Compositions and Methods for Enhancing Delivery of Nucleic Acids into Cells and for Modifying Expression of Target Genes in Cells
Method of Treating an Inflammatory Disease by Double Stranded Ribonucleic Acid
Rnai Therapeutic for Respiratory Virus Infection
Modification of Double-Stranded Ribonucleic Acid Molecules
Pharmaceutical Compositions for Delivery of Ribonucleic Acid to a Cell
Compounds and Methods for Peptide Ribonucleic Acid Condensate Particles for Rna Therapeutics
Peptide-Dicer Substrate Rna Conjugates as Delivery Vehicles for Sirna
Dicer Substrate Rna Peptide Conjugates and Methods for Rna Therapeutics
Nicked or Gapped Nucleic Acid Molecules and Uses Thereof
Nucleic Acid Compounds for Inhibiting Akt Gene Expression and Uses Thereof
Nucleic Acid Compounds for Inhibiting Erbb Family Gene Expression and Uses Thereof
Nucleic Acid Compounds for Inhibiting Vegf Family Gene Expression and Uses Thereof
Nucleic Acid Compounds for Inhibiting HIF1A Gene Expression and Uses Thereof
Nucleic Acid Compounds for Inhibiting BCL2 Gene Expression and Uses Thereof
Nucleic Acid Compounds for Inhibiting Myc Gene Expression and Uses Thereof
Nucleic Acid Compounds for Inhibiting Ras Gene Expression and Uses Thereof
Nucleic Acid Compounds for Inhibiting Wnt Gene Expression and Uses Thereof
Amino Acid Lipids and Uses Thereof
Hydroxymethyl Substituted Rna Oligonucleotides and Rna Complexes
Lipopeptides for Delivery of Nucleic Acids
Multi-Arm Amines and Uses Thereof
Nucleic Acid Compounds for Inhibiting BIRC5 Gene Expression and Uses Thereof
Nucleic Acid Compounds for Inhibiting PLK1 Gene Expression and Uses Thereof
Processes and Compositions for Liposomal and Efficient Delivery of Gene Silencing Therapeutics
Compositions and Methods for Triggered Release Rna Therapeutics
Usirna Complexes
Phage Displayed Trp Cage Ligands
Patent: 7,329,725 →
Application: 10/976,942 →
Double-stranded ribonucleic acid molecules having ribothymidine
Application: 11/219,625 →
Publication: US 2006/0142230
Pharmaceutical compositions for delivery of ribonucleic acid to a cell
Application: 11/223,699 →
Publication: US 2006/0035815
Method of Treating an Inflammatory Disease by Double Stranded Ribonucleic Acid
Application: 11/576,139 →
Publication: US 2010/0113332
COMPOSITIONS AND METHODS EMPLOYING UNIVERSAL-BINDING NUCLEOTIDES FOR TARGETING MULTIPLE GENE VARIANTS WITH A SINGLE siRNA DUPLEX
Application: 11/610,403 →
Publication: US 2007/0254362
Dry Powder Compositions for Rna Influenza Therapeutics
Application: 11/623,306 →
Publication: US 2007/0172430
Phage Displayed Cell Binding Peptides
Patent: 7,704,953 →
Application: 11/627,863 →
Publication: US 2007/0197444
CATIONIC PEPTIDES FOR siRNA INTRACELLULAR DELIVERY
Application: 11/676,221 →
Publication: US 2007/0275923
Compositions and Methods for Complexes of Nucleic Acids and Organic Cations
Application: 11/676,226 →
Publication: US 2007/0276134
Rnai Therapeutic for Respiratory Virus Infection
Application: 11/687,564 →
Publication: US 2007/0213293
COMPOSITIONS AND METHODS FOR LIPID AND POLYPEPTIDE BASED siRNA INTRACELLULAR DELIVERY
Application: 11/743,480 →
Publication: US 2007/0281900
FORMULATIONS FOR INTRACELLULAR DELIVERY dsRNA
Application: 11/750,979 →
Publication: US 2007/0269892
Device for Improved Peptide Delivery
Application: 11/774,492 →
Publication: US 2008/0029084
Rnai Therapeutic for Respiratory Virus Infection
Application: 11/910,971 →
Publication: US 2010/0254945
Phage Displayed Trp Cage Ligands
Patent: 8,063,178 →
Application: 11/955,207 →
Publication: US 2008/0096769
Methods and Compositions for Enhancing Delivery of Double-Stranded Rna or a Double-Stranded Hybrid Nucleic Acid to Regulate Gene Expression in Mammalian Cells
Application: 12/013,274 →
Publication: US 2008/0261304
Nucleic Acid Compounds for Inhibiting Vegf Gene Expression and Uses Thereof
Application: 12/039,650 →
Publication: US 2008/0286866
Nucleic Acid Compounds for Inhibiting Erbb Gene Expression and Uses Thereof
Application: 12/039,658 →
Publication: US 2008/0287383
Nucleic Acid Compounds for Inhibiting Akt Gene Expression and Uses Thereof
Application: 12/039,662 →
Publication: US 2008/0293136
Nucleic Acid Compounds for Inhibiting Apob Gene Expression and Uses Thereof
Application: 12/039,668 →
Publication: US 2008/0299659
Modification of Double-Stranded Ribonucleic Acid Molecules
Application: 12/065,604 →
Publication: US 2009/0018097
Amino Acid Lipids and Uses Thereof
Patent: 7,939,505 →
Application: 12/114,284 →
Publication: US 2008/0317839
Uses of Broad Spectrum Rnai Therapeutics Against Influenza
Application: 12/189,563 →
Publication: US 2009/0042823
Compositions and Methods for Enhancing Delivery of Nucleic Acids into Cells and for Modifying Expression of Target Genes in Cells
Patent: 8,299,236 →
Application: 12/206,165 →
Publication: US 2009/0042298
Ribonucleic Acids with Non-Standard Bases and Uses Thereof
Application: 12/486,889 →
Publication: US 2010/0015708
Hydroxymethyl Substituted Rna Oligonucleotides and Rna Complexes
Patent: 8,314,227 →
Application: 12/515,403 →
Publication: US 2010/0056768
Nucleic Acid Compounds for Inhibiting Vegf Family Gene Expression and Uses Thereof
Application: 12/528,508 →
Publication: US 2010/0047909
Nucleic Acid Compounds for Inhibiting Erbb Family Gene Expression and Uses Thereof
Application: 12/528,619 →
Publication: US 2010/0112687
Nucleic Acid Compounds for Inhibiting HIF1A Gene Expression and Uses Thereof
Application: 12/528,786 →
Publication: US 2010/0015706
Nucleic Acid Compounds for Inhibiting BCL2 Gene Expression and Uses Thereof
Application: 12/529,011 →
Publication: US 2010/0041140
Nucleic Acid Compounds for Inhibiting Myc Gene Expression and Uses Thereof
Application: 12/529,138 →
Publication: US 2010/0055782
Nucleic Acid Compounds for Inhibiting Ras Gene Expression and Uses Thereof
Application: 12/529,302 →
Publication: US 2010/0055783
Nucleic Acid Compounds for Inhibiting Wnt Gene Expression and Uses Thereof
Application: 12/529,532 →
Publication: US 2010/0055784
Nucleic Acid Compounds for Inhibiting Gene Expression and Uses Thereof
Application: 12/552,082 →
Publication: US 2010/0105134
Processes and Compositions for Liposomal and Efficient Delivery of Gene Silencing Therapeutics
Application: 12/580,250 →
Publication: US 2010/0112042
Nanoparticles for delivery of nucleic acids and stable double-stranded RNA
Application: 60/497,740 →
Phage displayed Trp cage ligands
Application: 60/515,533 →
Conjugation of a cholesterol moiety to double-stranded RNA or a double-stranded hybrid nucleic acid
Application: 60/564,543 →
Histones complexed or covalently bonded to double-stranded RNA to an RNA/DNA hybrid
Application: 60/568,027 →
Polylpeptides complexed or linked to double-stranded RNA or to an RNA/DNA hybrid with a cationic lipid
Application: 60/570,512 →
Polylpeptides complexed or covalently bonded to double-stranded RNA or to an RNA/DNA hybrid
Application: 60/570,513 →
Use of RNA interference to treat rheumatoid arthritis
Application: 60/613,416 →
Conjugation or complexation of a protein transduction domain and fusogenic polypeptide to a small interfering nucleic acid for use in RNA interference
Application: 60/656,572 →
Compositions and methods for RNA interference to treat rheumatoid arthritis
Application: 60/667,833 →
Anti-viral compositions and methods of use thereof
Application: 60/669,942 →
Chemically modified double-stranded ribonucleic acid molecules
Application: 60/720,072 →
Peptide-mediated sirna uptake into cells
Application: 60/727,216 →
Peptide mediated cellular uptake of double stranded RNA
Application: 60/733,664 →
Peptide-dicer substrate RNA conjugates as delivery vehicles for siRNA
Application: 60/733,665 →
FORMULATIONS FOR INTRACELLULAR DELIVERY dsRNA
Application: 60/747,622 →
Dry powder compositions
Application: 60/760,714 →
Phage displayed cell binding peptides
Application: 60/774,496 →
Compositions and methods employing universal-binding nucleotides for targeting multiple gene variants with a single siRNA duplex
Application: 60/796,274 →
Compositions and methods for lipid and polypeptide based siRNA intracellular delivery
Application: 60/798,243 →
Compositions and Methods for Complexes of Nucleic Acids and Organic Cations
Application: 60/803,065 →
CATIONIC PEPTIDES FOR siRNA INTRACELLULAR DELIVERY
Application: 60/803,175 →
COMPOSITIONS AND METHODS FOR LIPID-BASED siRNA INTRACELLULAR DELIVERY
Application: 60/805,327 →
Device for improved peptide delivery
Application: 60/821,528 →
Peptide-Dicer Substrate Rna Conjugates as Delivery Vehicles for Sirna
Application: 60/822,896 →
Phage Displayed Cell Binding Peptides
Application: 60/823,894 →
Compounds and Methods for Peptide Ribonucleic Acid Condensate Particles for Rna Therapeutics
Application: 60/825,878 →
COMPOSITIONS AND METHODS EMPLOYING GAPPED OR NICKED siRNA MOLECULES
Application: 60/862,027 →
Compositions and Methods of Using Gapped or Nicked Double Stranded Nucleic Acid Molecules
Application: 60/910,393 →
Amino Acid Lipid Compositions and Methods for Delivering Rna Therapeutics
Application: 60/916,131 →
Nucleic Acid Compounds for Inhibiting Vegf Family Gene Expression and Uses Thereof
Application: 60/932,949 →
Nucleic Acid Compounds for Inhibiting Erbb Family Gene Expression and Uses Thereof
Application: 60/932,970 →
Nucleic Acid Compounds for Inhibiting ERBB4 Gene Expression and Uses Thereof
Application: 60/934,922 →
Nucleic Acid Compounds for Inhibiting Vegfb Gene Expression and Uses Thereof
Application: 60/934,928 →
Compounds for Inhibiting Gene Expression by Ribonucleic Acid Interference and Uses Thereof
Application: 60/934,930 →
Nucleic Acid Compounds for Inhibiting Vegf Gene Expression and Uses Thereof
Application: 60/934,931 →
Nucleic Acid Compounds for Inhibiting Pgf Gene Expression and Uses Thereof
Application: 60/934,934 →
Nucleic Acid Compounds for Inhibiting ERBB3 Gene Expression and Uses Thereof
Application: 60/934,935 →
Compounds for Inhibiting Tnf Gene Expression by Ribonucleic Acid Interference and Uses Thereof
Application: 60/934,940 →
Nucleic Acid Compounds for Inhibiting Figf Gene Expression and Uses Thereof
Application: 60/934,943 →
Nucleic Acid Compounds for Inhibiting Egfr Gene Expression and Uses Thereof
Application: 60/934,945 →
Nucleic Acid Compounds for Inhibiting ERBB2 Gene Expression and Uses Thereof
Application: 60/934,946 →
Amino Acid Lipid Compositions and Methods for Delivering Rna Therapeutics
Application: 60/947,282 →
Amino Acid Lipid Compositions and Methods for Delivering Rna Therapeutics
Application: 60/953,667 →
Rna Therapeutics for Drug Resistant Influenza
Application: 60/955,314 →
Compositions and Methods of Using Double-Stranded Nucleic Acid Molecules Containing One or More Gap or Nick
Application: 60/955,317 →
Nucleic Acid Compounds for Inhibiting HIF1A Gene Expression and Uses Thereof
Application: 60/956,093 →
Emulsion Compositions for Interfering Rna and Uses Thereof
Application: 60/972,590 →
Amino Acid Lipids and Uses for Rna Therapeutics
Application: 60/972,653 →
Nucleic Acid Compounds for Inhibiting RAF1 Gene Expression and Uses Thereof
Application: 60/973,397 →
Nucleic Acid Compounds for Inhibiting AKT1 Gene Expression and Uses Thereof
Application: 60/973,398 →
Lipopeptides for Delivery of Interfering Rna Agents
Application: 60/976,894 →
Uses of Broad Spectrum Rnai Therapeutics Against Influenza
Application: 60/979,772 →
Nucleic Acid Compounds for Inhibiting Myc Gene Expression and Uses Thereof
Application: 60/988,395 →
Nucleic Acid Compounds for Inhibiting Nras Gene Expression and Uses Thereof
Application: 60/988,400 →
Nucleic Acid Compounds for Inhibiting Hras Gene Expression and Uses Thereof
Application: 60/988,401 →
Nucleic Acid Compounds for Inhibiting Kras Gene Expression and Uses Thereof
Application: 60/988,402 →
Nucleic Acid Compounds for Inhibiting BCL2 Gene Expression and Uses Thereof
Application: 60/989,419 →
Nucleic Acid Compounds for Inhibiting AKT2 Gene Expression and Uses Thereof
Application: 61/013,212 →
Nucleic Acid Compounds for Inhibiting AKT3 Gene Expression and Uses Thereof
Application: 61/013,239 →
Nucleic Acid Compounds for Inhibiting WNT3A Gene Expression and Uses Thereof
Application: 61/015,611 →
Dispersion Compositions for Interfering Rna and Uses Thereof
Application: 61/022,571 →
Lipophilic Amines and Uses Thereof
Application: 61/057,153 →
Ribonucleic Acids with Non-Standard Bases and Uses Thereof
Application: 61/073,633 →
Nucleic Acid Compounds for Inhibiting BIRC5 Gene Expression and Uses Thereof
Application: 61/086,435 →
Nucleic Acid Compounds for Inhibiting PLK1 Gene Expression and Uses Thereo
Application: 61/086,445 →
Compositions and Methods for Liposomal Rna Therapeutics
Application: 61/106,062 →
Compositions and Methods for Triggered Release Therapeutics
Application: 61/116,258 →
Rna Oligonucleotides and Rna Complexes Comprising Acyclic Nucleomonomers
Application: 61/119,624 →
Compositions and Methods for Efficient Delivery of Gene Silencing Therapeutics
Application: 61/167,379 →
Rna Complexes Comprising Acyclic Nucleomonomers
Application: 61/252,085 →
Amino Acid-Based Nanoparticle Formulations
Application: 61/258,115 →
Related Assignments (15)
Other recorded transfers of the patents in this record — the chain of ownership.
Change of Name Dec 14, 2009
From: NASTECH PHARMACEUTICAL COMPANY INC.
To: MDRNA, INC.
Reel/Frame 023652/0031 →
Security Agreement Dec 29, 2009
From: MDRNA, INC.; MDRNA RESEARCH, INC.; NASTECH PHARMACEUTICAL COMPANY, INC.
To: EOS HOLDINGS LLC, AS AGENT
Reel/Frame 023708/0389 →
Change of Name Jan 21, 2010
From: NASTECH PHARMACEUTICAL COMPANY INC.
To: MDRNA, INC.
Reel/Frame 023827/0675 →
Change of Name Feb 10, 2010
From: NASTECH PHARMACEUTICAL COMPANY INC.
To: MDRNA, INC.
Reel/Frame 023915/0694 →
Change of Name Feb 25, 2010
From: NASTECH PHARMACEUTICAL COMPANY, INC.
To: MDRNA, INC.
Reel/Frame 023993/0447 →
Security Agreement (Patents) Apr 28, 2010
From: MDRNA, INC. FKA NASTECH PHARMACEUTICAL COMPANY INC.
To: CEQUENT PHARMACEUTICALS, INC.
Reel/Frame 024300/0825 →
Assignment of Assignor's Interest May 27, 2010
From: ADAMI, ROGER C; HOUSTON, MICHAEL E, JR; JOHNS, RACHEL E
To: NASTECH PHARMACEUTICAL COMPANY INC.
Reel/Frame 024452/0344 →
Release of Security Interest Jul 30, 2010
From: CEQUENT PHARMACEUTICALS, INC.
To: MARINA BIOTECH, INC. (F/K/A MDRNA, INC.)
Reel/Frame 024767/0466 →
Change of Name Aug 19, 2010
From: MDRNA, INC.
To: MARINA BIOTECH, INC.
Reel/Frame 024863/0425 →
Change of Name Oct 13, 2010
From: MDRNA, INC.
To: MARINA BIOTECH, INC.
Reel/Frame 025128/0691 →
Security Agreement Feb 15, 2012
From: MARINA BIOTECH, INC; CEQUENT PHARMACEUTICALS, INC.; MDRNA RESEARCH, INC.
To: GENESIS CAPITAL MANAGEMENT, LLC, AS AGENT
Reel/Frame 027712/0200 →
Security Agreement May 13, 2013
From: MARINA BIOTECH, INC.; CEQUENT PHARMACEUTICALS, INC.; MDRNA RESEARCH, INC.
To: MONSANTO COMPANY
Reel/Frame 030401/0461 →
Assignment of Assignor's Interest Aug 20, 2013
From: MARINA BIOTECH, INC.
To: ARCTURUS THERAPEUTICS, INC.
Reel/Frame 031047/0842 →
Release of Security Interest Apr 14, 2014
From: GENESIS CAPITAL MANAGEMENT, LLC, AS AGENT
To: MARINA BIOTECH, INC.; CEQUENT PHARMACEUTICALS, INC.; MDRNA RESEARCH, INC.
Reel/Frame 032685/0158 →
Security Interest Nov 23, 2021
From: ADHERA THERAPEUTICS, INC.
To: CAVALRY FUND I LP
Reel/Frame 058312/0195 →